<DOC>
	<DOCNO>NCT02401737</DOCNO>
	<brief_summary>This Phase 1b trial ass dose-related safety PK profile different dos NVR 3-778 patient chronic hepatitis B. Additionally , change patient ' serum HBV DNA level virologic efficacy parameter assess .</brief_summary>
	<brief_title>Dose-Ranging Study Assess Safety , PK Initial Antiviral Efficacy NVR 3-778 Chronic HBV Patients</brief_title>
	<detailed_description>The Phase 1b assessment dose-related safety , PK , initial antiviral efficacy NVR 3-778 hepatitis B patient also conduct approximately 14 different site meet enrollment goal 54-84 chronic hepatitis B patient . To promote objective safety tolerance assessment trial , study subject , site personnel administer study drug perform clinical assessment subject , blind individual subject ' treatment assignment ( active NVR 3-778 placebo dos ) , treatment cohort study . Study advancement subsequent patient cohort require satisfactory interim review available cumulative safety data Safety Review Committees ( SRC ) , use safety criterion review procedure describe protocol . Also , one interim review safety data independent Safety Monitoring Board ( SMB ) , describe protocol .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patients may male female 18 65 year age , BMI 1835kg/m2 . Patients must HBeAg positive chronic hepatitis B history clinical decompensation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Hepatitis B</keyword>
</DOC>